Aptose Biosciences Inc. (APTO) Trading Down 4.1%
Aptose Biosciences Inc. (NASDAQ:APTO) dropped 4.1% during trading on Tuesday . The company traded as low as $2.09 and last traded at $2.09, with a volume of 73,186 shares. The stock had previously closed at $2.18.
APTO has been the topic of a number of recent research reports. Canaccord Genuity reissued a “buy” rating and issued a $7.00 target price on shares of Aptose Biosciences in a research note on Thursday, June 9th. Royal Bank Of Canada reissued an “outperform” rating and issued a $23.00 target price on shares of Aptose Biosciences in a research note on Saturday, June 25th. Roth Capital raised Aptose Biosciences from a “neutral” rating to a “buy” rating and increased their target price for the stock from $4.00 to $8.00 in a research note on Monday, June 13th. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of Aptose Biosciences in a research note on Thursday, June 9th. Finally, Zacks Investment Research cut Aptose Biosciences from a “hold” rating to a “sell” rating in a research note on Friday, August 12th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $12.30.
The company’s 50 day moving average is $2.38 and its 200-day moving average is $2.59. The firm’s market cap is $26.94 million.
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.